Sreeram V. Ramagopalan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Sreeram V. Ramagopalan has a total of 193 co-authors. Here are the top co-authors by number of shared publications:
Alex Simpson
Global Access, F. Hoffmann-La Roche, Basel, Switzerland
15 shared publicationsLaura McDonald
Centre for Observational Research & Data Sciences, Bristol-Myers Squibb, Uxbridge UB8 1DH, UK
14 shared publicationsPaul Arora
Division of Epidemiology, Dalla Lana School of Public Health, University of Toronto, Toronto, ON M5T 3M7, Canada
12 shared publicationsAnnie Jullien Pannelay
Université Paris Saclay, UFR Pharmacie, Orsay, France
10 shared publicationsFaisal Mehmud
Bristol-Myers Squibb, Uxbridge, UK
8 shared publicationsRobert Carroll
Centre for Observational Research & Data Sciences, Bristol-Myers Squibb, Uxbridge, UK
8 shared publications
Latest Publications
- Open Access
- 1 July 2026
- Published by Becaris Publishing Limited in Journal of Comparative Effectiveness Research
- Vol. 15 (7) , e260110
Most-Favored-Nation pricing meets Joint Clinical Assessment: early evidence of compounding pressure on European drug launches
- 1 July 2026
- Published by Becaris Publishing Limited in Journal of Comparative Effectiveness Research
- Vol. 15 (7) , e260110
Open AccessMost-Favored-Nation pricing meets Joint Clinical Assessment: early evidence of compounding pressure on European drug launches
- Open Access
- 1 July 2026
- Published by Becaris Publishing Limited in Journal of Comparative Effectiveness Research
- Vol. 15 (7) , e260117
Access in all areas? A round-up of developments in market access and health technology assessment: first Joint Clinical Assessment report released
The first Joint Clinical Assessment (JCA) report has been completed. In this update we examine what this inaugural report reveals in practice and draw out the implications for manufacturers.
- 1 July 2026
- Published by Becaris Publishing Limited in Journal of Comparative Effectiveness Research
- Vol. 15 (7) , e260117
Open AccessAccess in all areas? A round-up of developments in market access and health technology assessment: first Joint Clinical Assessment report released
The first Joint Clinical Assessment (JCA) report has been completed. In this update we examine what this inaugural report reveals in practice and draw out the implications for manufacturers.
- Open Access
- 1 July 2026
- Published by Becaris Publishing Limited in Journal of Comparative Effectiveness Research
- Vol. 15 (7) , e260074
R WE ready for reimbursement? A round-up of developments in real-world evidence relating to health technology assessment: part 26
In this update, we review a framework for identifying and mitigating information bias in electronic health records and administrative claims data, highlighting practical recommendations for study design, variable definition, and statistical analysis. We also discuss a perspective on emerging privacy-preserving technologies – synthetic data and federated networks – that enable secure cross-border data access while maintaining patient privacy.
- 1 July 2026
- Published by Becaris Publishing Limited in Journal of Comparative Effectiveness Research
- Vol. 15 (7) , e260074
Open AccessR WE ready for reimbursement? A round-up of developments in real-world evidence relating to health technology assessment: part 26
In this update, we review a framework for identifying and mitigating information bias in electronic health records and administrative claims data, highlighting practical recommendations for study design, variable definition, and statistical analysis. We also discuss a perspective on emerging privacy-preserving technologies – synthetic data and federated networks – that enable secure cross-border data access while maintaining patient privacy.
- Open Access
- 1 June 2026
- Published by Becaris Publishing Limited in Journal of Comparative Effectiveness Research
- Vol. 15 (6) , e260073
R WE ready for reimbursement? A round-up of developments in real-world evidence relating to health technology assessment: part 25
In this update, we discuss the use of real-world data in the Haute Autorité de Santé assessment of economic evaluations, review how real-world evidence is supporting regulatory approvals in multiple myeloma, and consider lessons from the failed EVOKE trials of semaglutide in Alzheimer's disease for the broader application of target trial emulation.
- 1 June 2026
- Published by Becaris Publishing Limited in Journal of Comparative Effectiveness Research
- Vol. 15 (6) , e260073
Open AccessR WE ready for reimbursement? A round-up of developments in real-world evidence relating to health technology assessment: part 25
In this update, we discuss the use of real-world data in the Haute Autorité de Santé assessment of economic evaluations, review how real-world evidence is supporting regulatory approvals in multiple myeloma, and consider lessons from the failed EVOKE trials of semaglutide in Alzheimer's disease for the broader application of target trial emulation.
- Top Cited PapersOpen Access
- 1 May 2026
- Published by Becaris Publishing Limited in Journal of Comparative Effectiveness Research
- Vol. 15 (5) , e260056
Access in all areas? A round-up of developments in market access and health technology assessment: part 14
In this update we examine the selection of 15 drugs for the third cycle of Medicare price negotiations under the Inflation Reduction Act and analyze emerging evidence of the Most-Favored-Nation impact on global pharmaceutical access, including launch delays and market withdrawals. We also review recent research on the tension between US patient values and foreign health technology assessment frameworks and discuss the review of the first year of implementation of the Joint Clinical Assessment procedure in Europe.
- 1 May 2026
- Published by Becaris Publishing Limited in Journal of Comparative Effectiveness Research
- Vol. 15 (5) , e260056
Top Cited PapersOpen AccessAccess in all areas? A round-up of developments in market access and health technology assessment: part 14
In this update we examine the selection of 15 drugs for the third cycle of Medicare price negotiations under the Inflation Reduction Act and analyze emerging evidence of the Most-Favored-Nation impact on global pharmaceutical access, including launch delays and market withdrawals. We also review recent research on the tension between US patient values and foreign health technology assessment frameworks and discuss the review of the first year of implementation of the Joint Clinical Assessment procedure in Europe.
- Open Access
- 1 April 2026
- Published by Becaris Publishing Limited in Journal of Comparative Effectiveness Research
- Vol. 15 (4) , e260041
Access in all areas? A round-up of developments in market access and health technology assessment: part 13
In this update we cover the US–UK Economic Prosperity Deal announced in December 2025, which includes NICE's first major cost-effectiveness threshold increase in over two decades. We also analyze the latest developments in US pharmaceutical pricing policy, including the second cycle of Inflation Reduction Act drug price negotiations and the implementation of the GENEROUS, GUARD and GLOBE Models for Most-Favored-Nation pricing.
- 1 April 2026
- Published by Becaris Publishing Limited in Journal of Comparative Effectiveness Research
- Vol. 15 (4) , e260041
Open AccessAccess in all areas? A round-up of developments in market access and health technology assessment: part 13
In this update we cover the US–UK Economic Prosperity Deal announced in December 2025, which includes NICE's first major cost-effectiveness threshold increase in over two decades. We also analyze the latest developments in US pharmaceutical pricing policy, including the second cycle of Inflation Reduction Act drug price negotiations and the implementation of the GENEROUS, GUARD and GLOBE Models for Most-Favored-Nation pricing.
- Open Access
- 1 March 2026
- Published by Becaris Publishing Limited in Journal of Comparative Effectiveness Research
- Vol. 15 (3) , e260019
R WE ready for reimbursement? A round-up of developments in real-world evidence relating to health technology assessment: part 24
In this update, we review a new bias appraisal tool, explore lessons from a trial emulation study, and describe the development of real-world evidence guidance in the Philippines.
- 1 March 2026
- Published by Becaris Publishing Limited in Journal of Comparative Effectiveness Research
- Vol. 15 (3) , e260019
Open AccessR WE ready for reimbursement? A round-up of developments in real-world evidence relating to health technology assessment: part 24
In this update, we review a new bias appraisal tool, explore lessons from a trial emulation study, and describe the development of real-world evidence guidance in the Philippines.
- Open Access
- 1 February 2026
- Published by Becaris Publishing Limited in Journal of Comparative Effectiveness Research
- Vol. 15 (2) , e250208
Access in all areas? A round-up of developments in market access and health technology assessment: part 12
In this update we cover the impacts of the US Most Favored Nation pricing policy and research evaluating drug availability and affordability in China as a result of the National Reimbursement Drug List negotiation policy.
- 1 February 2026
- Published by Becaris Publishing Limited in Journal of Comparative Effectiveness Research
- Vol. 15 (2) , e250208
Open AccessAccess in all areas? A round-up of developments in market access and health technology assessment: part 12
In this update we cover the impacts of the US Most Favored Nation pricing policy and research evaluating drug availability and affordability in China as a result of the National Reimbursement Drug List negotiation policy.
- Open Access
- 15 December 2025
- Published by Becaris Publishing Limited in Journal of Comparative Effectiveness Research
- Vol. 15 (1) , e250196
R WE ready for reimbursement? A round-up of developments in real-world evidence relating to health technology assessment: part 23
In this update, we explore a review on transportability methods to enable the use of cross-jurisdictional evidence when local data are limited, a review of clinical trials that use pragmatic elements and finally, we discuss a study highlighting the potential transformative role of large language models in disease progression modeling.
- 15 December 2025
- Published by Becaris Publishing Limited in Journal of Comparative Effectiveness Research
- Vol. 15 (1) , e250196
Open AccessR WE ready for reimbursement? A round-up of developments in real-world evidence relating to health technology assessment: part 23
In this update, we explore a review on transportability methods to enable the use of cross-jurisdictional evidence when local data are limited, a review of clinical trials that use pragmatic elements and finally, we discuss a study highlighting the potential transformative role of large language models in disease progression modeling.
- Open Access
- 1 December 2025
- Published by Becaris Publishing Limited in Journal of Comparative Effectiveness Research
- Vol. 14 (12) , e250176
Access in all areas? A round-up of developments in market access and health technology assessment: part 11
In this update, we cover the evolving health technology assessment process in Australia and also examine how commercial health plans in the US influence patient access to treatments.
- 1 December 2025
- Published by Becaris Publishing Limited in Journal of Comparative Effectiveness Research
- Vol. 14 (12) , e250176
Open AccessAccess in all areas? A round-up of developments in market access and health technology assessment: part 11
In this update, we cover the evolving health technology assessment process in Australia and also examine how commercial health plans in the US influence patient access to treatments.